valuat appear reflect potenti upsid
summari initi coverag equal weight
rate price target assum
revenu estim estim dxcm core
continu glucos monitor cgm market one
fastest grow major med-tech market next five year
see potenti upsid consensu sale ep estim
believ valuat reflect potenti sourc
upsid would prefer wait either better entri point
greater visibl major new market opportun type
non-insulin intens recommend share
cgm fastest grow major med-tech market
estim ww cgm market grow
compound-annual-growth-rate cgm replac fingerstick
test diabet patient estim includ revenu
current type type insulin-intens ii diabet
segment assum penetr cgm increas
dxcm pipelin opportun come focu
repres dxcm import new product opportun
improv form factor longer wear-tim vs
current full dispos plan launch
although pivot trial delay month due
also number new market opportun
hospit set gestat diabet type non-
insulin intens diabet patient expect greater visibl
time new market opportun
see upsid potenti estim revenu
estim consensu
y/i reflect impact
benefit record new patient start histor
season analysi impli sale
consensu less season
compani shift pharmaci channel one-third
upsid impli analysi vs consensu intern
shift pharmaci factor
valuat appear reflect sourc upsid
stock run ytd vs
current trade consensu revenu vs
high-growth med-tech group median remain
posit dxcm long-term fundament leader cgm
long runway growth ahead opt stay sidelin
equal weight rate look appropri
entri point ep
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
initi coverag
compani data secur llc estim reuter
compani data secur llc estim reuter
tabl content
shift pharmaci channel
initi coverag inc equal weight rate price target
believ pure play medic devic compani focus continu glucos monitor cgm
devic diabet manag compani current target market primarili compos type
type diabet use insulin pump therapi multipl daili insulin inject
believ cgm market fastest grow major end market med-tech current type
type insulin-intens ii segment alon estim world-wide cgm market
grow compound-annual-growth-rate assum penetr cgm increas
expect cgm technolog continu replac fingerstick test
diabet patient
view repres import new product opportun ahead
improv form factor longer wear-tim current addit full
dispos plan launch although pivot trial delay six
month due also number market expans opportun
hospit set gestat diabet type non-insulin-intens patient
move financi revenu estim consensu
respect though model world-wide new patient start year year
reflect impact note benefit record number new
patient start conduct season analysi impli revenu
annual histor season past three year rel consensu
analysi impli potenti upsid respect forecast total
ww sale grow y/i
y/i model non-gaap ep y/i y/i
net-net estim dxcm core continu glucos monitor cgm market one
fastest grow major med-tech market next five year see upsid potenti
consensu sale ep estim believ valuat reflect potenti
sourc upsid would prefer remain sidelin either better entri point
greater visibl major new market opportun type non-insulin intens
recommend stock initi coverag equal weight rate
plenti runway exist core intens insulin market ww intens insulin preval
patient ou estim peopl
diagnos type diabet accord cdc estim approxim
peopl type diabet use intens insulin ii therapi taken togeth estim
total address market patient penetr cgm continu
glucos monitor end view ampl runway continu drive
cgm penetr higher core intens insulin market given popul larg
remain under-penetrated cgm new technolog continu drive increment patient
mm except per share oper ebitda compani report secur llc estim medic technolog
reduc attrit rate meaning expand access cgm via shift pharmaci
channel increas payer coverag believ penetr cgm continu grind
higher assum type penetr reach today type ii
penetr reach today
launch drive patient base higher reduc attrit full launch ww
could drive increas penetr signific uniqu upgrad compar current
competit devic previou devic includ sensor transmitt unit
shallow profil compar full dispos similar believ
involv simpl insert requir fingerstick send data straight smartphon note
work two-week life sensor would neutral abt competit edg
freestyl libr sensor lifespan produc lower cost
cost scale expect beyond believ new technolog differenti
help drive compani new patient base higher beyond new patient also believ would
reduc patient attrit technolog continu improv
opportun still earli inning estim total cgm market
opportun intern approxim assum peak penetr overal ou
intens insulin cgm market model ou market penetr hold
share end continu roll-out new intern market becom
import driver patient share februari obtain regulatori approv
australia south korea japan work launch market later
though also made decis accept reimburs japan base price
fingerstick-level product new data could help establish new categori reimburs real-
time cgm japan could also help drive increas patient adopt later model
intern sale growth y/i grow
could provid tailwind cgm given hospit util april fda
temporarili allow provid cgm system hospit support care
patient date hospit request devic compani plan produc
sensor hospit patient donat phone receiv hospit accord
wall street journal also announc may health canada temporarili author
expand use hospit remot monitor patient critic ill
pandem addit fda recent remov delay requir cgm data
clariti softwar allow faster data integr could potenti increas demand
new environ provis healthcar via telemedicin view expand use cgm
may remain durabl beyond pandem given demand accur reliabl cgm
system hospit set thu effort develop and/or approv cgm devic popul
may progress faster anticip
pipelin opportun could signific driver futur market growth revenu
gestat diabet cgm hospit set first non-ii estim
approxim patient type diabet intens insulin
estim approxim patient basal insulin cgm immateri non-ii
opportun current estim believ cgm reach penetr
time second prediabet repres larg popul approxim peopl
could potenti benefit cgm third estim approxim women
give birth everi year gestat diabet cgm could potenti use
diagnos europ ce mark pregnant women diabet along remov
contraind pregnanc fourth meaning futur opportun exist hospit set
estim elig patient opportun hospit includ
monitor hypoglycemia hospit stay pre-op monitor patient admit
hyperglycemia prior elect surgeri use cgm hospit provid valu proposit
hospit payor given reduct delay cancel increas length stay
lower cost offer libr could exert addit price pressur estim
 averag sell price asp per patient per year abbott libr cgm system approxim
approxim dxcm cgm system intern estim
abbott asp lower cost offer could put
price pressur addit price pressur gener exert third-parti payer
combin dxcm intent increas proport sale via differ sale channel
pharmaci price pressur could reduc futur revenu cost contain effort off-set
greater patient access believ pocket cost cgm import driver patient adopt
impact result addit price pressur ensu
payer patient accept cgm non-insulin intens segment
challeng non-insulin intens market patient non-insulin-intens type
diabet peopl prediabet peopl gestat diabet peopl diabet
hospit set repres larg opportun expand market howev accept cgm
technolog payer patient could slow numer factor includ lack awar
benefit cgm insuffici data support use cgm inertia current standard
care popul driven hesit patient payer move away tradit
therapi studi evalu use cgm popul way howev
studi expect complet
disrupt could pose challeng note earn call
temporarili suspend guidanc compani greater visibl outlook given
current econom global health environ in-person doctor offic visit declin new patient
start could affect note survey indic new patient
start might sequenti though compani seen magnitud
impact actual begun see new patient start return addit unemploy exist
patient could lead increas attrit rate patient still afford discount cost
offer dxcm financi assist program furthermor global suppli chain remain
stabl far remain unpredict could interrupt current environ
model robust top-lin growth come year see sever potenti near longer
term driver growth includ new indic next-gener technolog scale
manufactur capabl intern expect growth driven
increas penetr exist market segment increas devic coverag access via
conveni sale channel later expect make avail south korea japan
australia could potenti move forward limit intern launch pend time
pivot trial compani expect full launch includ also made
inroad new market opportun pregnant women hospit patient non-intens type
diabet expect growth beyond driven launch penetr
core intens insulin market new geographi forecast total ww sale grow
y/i y/i beyond model
y/i y/i y/i
histor season suggest upsid potenti consensu estim
world-wide new patient start y/i reflect impact revenu
estim consensu respect note
benefit record number new patient start frame
took look histor quarterli season use averag sequenti growth
past three year math impli furthermor analysi impli
revenu annual histor season past three year
rel consensu analysi impli upsid potenti
respect acknowledg less season compani shift
pharmaci channel less affect patient deduct dme note one-third
upsid impli intern pharmaci channel impact factor overal
see growth target achiev believ possibl upsid exist consensu
exhibit season analysi impli upsid
mm
 assumpt term estim gross margin compar
term oper spend expect increas spend second half
around new manufactur site malaysia direct-to-consum market scale-up
product new market invest addit cost associ pivot trial would
origin contribut spend first half howev like add spend
second half result delay due current model sg spend
sale sale see exhibit
forecast expens sale sale
respect see exhibit also model oper margin increas
model non-gaap ep increas
y/i see exhibit
balanc sheet assumpt estim free cash flow grow
term capit structur estim
compani cash also estim
compani debt respect compar
debt year-end
factset secur llc estim
estimatesconsensusimpli season mm except per share oper ebitda inc
exhibit sale ep vs consensu
initi coverag equal weight rate price target price target
base ev/sal multipl revenu estim year date stock
run vs valuat perspect believ
high-growth med-tech compani appropri peer select high-growth med-tech
group trade median consensu revenu estim diabet group trade
median consensu revenu estim perspect trade consensu
revenu grow slower vs high growth med-tech group
diabet group exhibit believ premium appropri given consist
execut attract end market diabet profit howev believ potenti upsid
consensu estim reflect current stock price remain posit compani
long-term fundament leader cgm long runway growth ahead opt stay
sidelin equal weight rate look appropri entri point risk
achiev price target includ delay fda approv launch next gener devic
slower-than-expect adopt cgm competit
exhibit comp valuat
diabet mellitu diseas involv inabl regul blood sugar diabet consist two
major type type diabet lack insulin product type diabet insulin insensit
vs vs factset secur llc estim wf estim medic medic medic modul hldg diabet group factset averag ntm ev/sal multipl year current ev/ sale estim calender data medic nolog
type diabet type diabet autoimmun disord character absenc
insulin due destruct insulin-produc pancreat cell normal develop
childhood therefor peopl type diabet depend insulin inject regul maintain
blood glucos level type diabet account diabet case accord
type diabet type diabet metabol disord character inabl produc
suffici level insulin insulin resist peopl type diabet requir vari type
treatment regul maintain blood sugar level depend sever disord
includ diet nutrit manag exercis oral medic insulin inject type diabet
account diabet accord ada estim approxim
patient type diabet intens insulin therapi
compani report secur llc estim
prediabet prediabet health condit character higher normal blood sugar level
yet high enough diagnos type diabet elev blood sugar level due
bodi inabl produc enough insulin overcom insulin resist set stage
type diabet futur accord cdc
gestat diabet gestat diabet type diabet develop pregnanc
women dont alreadi diabet character insulin resist bodi
inabl produc enough insulin pregnanc pregnant women experi insulin
resist late pregnanc women develop insulin resist becom pregnant
women start pregnanc increas necess insulin like develop
gestat diabet accord cdc note gestat diabet differ
women pregnant type type diabet
continu glucos monitor cgm devic track glucos level hour day real time
signific improv blood glucos meter provid singl glucos read
requir patient fingerstick cgm patient gain valuabl insight glucos level rate
direct chang proactiv manag diabet cgm devic integr
insulin pump autom deliveri use stand-alon basi patient inject insulin
current cgm market consist primarili peopl type diabet insulin-intens type
diabet type diabet insulin pump therapi multipl daili insulin
inject type diabet must take insulin order control blood glucos level type
diabet unlik type larg requir insulin initi even lifetim accord
ada howev diet exercis oral medic and/or medic suffici
control blood glucos level patient may requir insulin inject accord intern
diabet feder peopl type diabet may take insulin vari level intens rang
daili multipl inject per day
larg under-penetrated grow market opportun global estim
approxim patient diabet intens insulin grow
see exhibit global intens insulin averag instal base stood patient
repres penetr averag instal base held share follow
patient million yeartyp non-intens insulintyp intens insulintyp inc
revenu perspect cgm market
largest share follow look ahead
estim global cgm market grow compound-annual-growth-rate
see exhibit
exhibit ww insulin intens diabet popul
exhibit total ww averag instal base penetr ii
 approxim patient diabet intens insulin grow
estim see exhibit insulin-intens averag instal
base stood repres penetr averag instal base compani
abbott held share follow type market
penetr largest share follow
type ii market penetr base instal base
largest share follow share share revenu
patient average instal base untap ii average instal base cgm penetr base instal untap ii cgm revenu cgm revenu medic technolog
perspect cgm market y/i growth
largest share follow see exhibit estim
cgm market grow compound-annual-growth-rate see exhibit
believ penetr cgm continu grind higher come year
assum type penetr base instal base reach today
type ii penetr reach today see exhibit
exhibit total averag instal base penetr ii
patient million yeartyp intens insulintyp average instal base untap ii average instal base cgm penetr base instal untap ii cgm revenu cgm revenu inc
move intern estim approxim patient diabet
intens insulin grow see exhibit intern intens insulin
averag instal base stood patient repres penetr
averag instal base held share follow
revenu perspect intern cgm market largest
share follow see exhibit estim
intern cgm market grow compound-annual-growth-rate
see exhibit believ penetr intern cgm market also continu increas
come year see exhibit refer dxcm intern oper
current includ direct sale forc canada austria germani switzerland
distribut arrang australia new zealand countri africa asia europ latin america
middl east
exhibit total ou averag instal base penetr ii
term new patient addit estim approxim new patient
cgm global held share held share held
share note repres record number quarterli global new patient addit
new patient cgm share
close follow share share new patient intern
estim approxim new patient start use cgm devic
lead share follow share share new
inc medic devic compani focus continu glucos monitor cgm
devic diabet manag headquart san diego ca found launch
first gener cgm launch latest gener system integr
average instal base untap ii average instal base cgm penetr base instal untap ii cgm revenu cgm revenu medic technolog
continu glucos monitor system compani current target market primarili
compos peopl type type diabet use insulin pump therapi multipl daili
insulin inject compani also continu target peopl type diabet multipl daili
inject therapi expect expand target market diabet peopl pre-diabet peopl obes
peopl pregnant peopl peopl hospit set compani on-going clinic trial
involv current next gener cgm system clinic success increment area would
potenti enabl expand reimburs commerci devic new market
establish new class dxcm latest-gener system integr
continu glucos monitor system icgm classifi class ii devic fda
first type cgm system permit fda use part integr system
compat medic devic electron interfac autom insulin dose aid system
insulin pump blood glucos meter electron devic use manag diabet
also indic fda use stand-alon cgm obtain market
author fda march determin glucos level children two year age
older adult diabet market author obtain de novo process
provid way classifi novel medic devic gener and/or special control provid
reason assur effect safeti devic intend use
legal market predic devic accord fda
compar mobil requir minimum two fingerstick per day calibr
elimin fingerstick sensor applic transmitt redesign user-
friendli sensor allow simpler one-touch self-insert transmitt allow
comfort wear lower profil previou gener system new featur
also allow increas accuraci glucos read without interfer common
medic sensor use extend day allow longer wear compar
previou gener system new alert featur predict hypoglycemia help patient
avoid danger low blood sugar event manufactur doubl capac cours
support patient demand
mobil receiv fda approv august becam first cgm system
 receiv non-adjunct indic fda decemb mobil transmitt
commun directli patient compat mobil devic label use life three
month dispos sensor insert user use continu seven day
non-adjunct indic expand use mobil replac fingerstick glucos
test diabet treatment decis new label indic also vital step provid cgm
access peopl medicar allow mobil requir two fingerstick per day
calibr mobil requir confirmatori fingerstick treatment decis ou
region recogn ce mark well canada
platinum replac seven system approv earli
seven day continu use adult diabet indic adjunct devic
complement replac inform standard home blood glucos monitor devic
platinum must calibr initi use measur two fingerstick thereaft least
everi hour use fingerstick test note order clear way dxcm next
gener cgm plan discontinu platinum mobil cgm
transmitt june discontinu platinum mobil cgm sensor end
exhibit histori regulatori event
found base research implant long-perform glucos
sensor bodi would reject
dxcm short-term sensor program creat
dxcm initi public offer ipo nasdaq stock market announc
first gener st cgm launch help peopl
diabet manag blood sugar level
seven cgm launch first cgm system approv
seven continu day use
third gener seven launch
platinum launch advanc cgm
system avail time overal accuraci eas use
platinum cgm share launch allow
patient share glucos inform five peopl via
share follow app smart devic
mobil cgm launch becam first
fulli mobil cgm system allow adult children two year older
abil monitor glucos level compat smart devic well
share glucos data
fda approv non-adjunct label mobil cgm
design system replac fingerstick glucos test
center medicar medicaid servic classifi therapeut cgm
durabl medic equip mobil cgm first cgm
system fall classif
mobil app android devic receiv fda approv allow
android user access free app mobil cgm
first cgm platform avail android time
fda grant market author icgm system
receiv conformit europeenn market ce mark approv
enabl compani market system european union
asian latin american countri recogn ce mark new zealand
receiv market author fda
intend healthcar profession use day
patient age two year older mani featur
compani report websit secur llc
near-term catalyst includ launch increas roll-out
particularli ou integr cgm technolog partnership increas coverag
payer patient type diabet intens insulin dxcm focu increas
pharmaci channel base acceler need cgm devic hospit set due covid-
collect believ near-term catalyst support increas patient share
come quarter year
meaning new technolog launch potenti limit intern
launch late pend time delay pivot trial due full launch
includ could drive increas penetr signific uniqu
upgrad sensor transmitt unit compar separ unit previou
gener competitor also shallow profil
work two-week life sensor test pivot trial would elimin
freestyl libr system competit edg sensor lifespan addit receiv fda
approv octob launch devic could drive adopt new patient
reduc attrit rate data gather would allow provid adjust custom
patient diabet therapi plan precis
roll-out new intern market import grow patient share
februari obtain regulatori approv australia south korea japan
work launch market later though also made decis
accept reimburs japan base price fingerstick-level product new data could drive
better reimburs real-tim cgm could also help drive increas patient adopt later
partnership drive patient share integr cgm technolog
companion medic inpen omnipod horizon system autom insulin deliveri expect launch
smart pen offer lilli expect launch novo nordisk smart pen beta
bionic ilet expect launch beyond appl watch ypsome mylif app
expect launch late could posit benefit multipl commerci
system next year potenti drive increas patient share
shift pharmaci channel increas payer coverag meaning improv access cgm
intend shift commerci sale channel breakdown includ larger pharmaci portion
smaller dme portion long-term goal commerci base come
pharmaci channel estim end dxcm averag commerci
instal base pharmaci channel major compani new patient addit
 came pharmaci channel pharmaci channel effici expect reduc
amount time take patient get product week day
reduc amount paperwork involv get patient start devic expect
shift pharmaci channel help drive increas share among patient type diabet though
shift pharmaci would decreas asp per patient per year expect pharmaci asp
dme asp would also make dxcm devic easili
access patient could attract new patient technolog also expect increas
sale volum due shift pharmaci channel therebi make decreas revenu per
patient per year long term expect eros medicar coverag
forthcom launch
regard payer coverag unit healthcar began provid coverag peopl type
diabet intens insulin april also note earn call
anoth larg payer expand type intens use polici though yet provid detail
payer expect coverag new payer take effect around middl
coverag addit medicar demonstr increas traction compani gain
type intens insulin market larg payer furthermor announc april
enforc restrict type diabet beneficiari must requir
demonstr need frequent blood glucos test patient receiv therapeut
cgm cover medicar expand coverag intend valid
pandem could act catalyst expand access cgm longer term could drive
recognit potenti benefit cgm patient beyond tradit cover medicar
pandem could tailwind cgm given hospit util final
acceler realiz potenti benefit provid cgm system hospit set due
could valid dxcm valu proposit hospit popul april result
pandem fda allow provid cgm system hospit
support care patient histor ship cgm system
hospit approv fda inpati use howev patient alreadi
use devic allow continu use hospit discret physician
devic could reduc risk viral transmiss reduc necess nurs perform blood
glucos test via fingerstick blood draw infect patient diabet approxim
hospit request devic compani plan produc sensor
hospit patient donat phone receiv hospit accord wall street
journal health canada also recent temporarili author expand use hospit
remot monitor patient critic ill pandem view expand
use cgm may remain durabl beyond pandem given demand accur
reliabl cgm system hospit set effort develop and/or approv cgm devic
popul may progress faster anticip
meaning product launch ahead full launch
expect limit launch potenti late pend time pivot trial
earn call note time pivot trial would delay minimum
around six month due new trial clinic site paus respons next
gener devic shallow profil compar fulli dispos
involv simpl insert compani work toward two-week life sensor pend trial
result sensor transmitt unit compar separ unit previou
gener product addit produc lower cost amount
produc cost scale expect approxim continu prepar
scale-up manufactur line look support sale growth increas direct-to-
increment iter technolog launch first
single-us profession cgm gather real-tim glucos data period offer
blind unblind mode blind mode real-tim glucos data hidden patient
review healthcar profession retrospect end session unblind
mode patient abl see glucos data throughout sensor wear healthcar
provid view retrospect data patient glucos pattern period use
data adjust patient diabet therapi plan necessari easi sensor
applic one-touch insert single-us dispos sensor read glucos valu
automat everi five minut auto-start transmitt alert alarm warn danger
high low glucos level unblind mode also expect requir fingerstick
calibr treatment decis clariti allow provid view interact report
review glucos pattern trend statist patient retrospect plan
launch pro
respect new opportun also explor extend offer peopl pre-
diabet peopl pregnant peopl hospit set peopl type diabet
intens insulin intend expand effort accumul cgm patient data appli
predict model machin learn order creat interact cgm insight inform
behavior patient
pre-diabet estim approxim peopl pre-diabet
peopl could potenti benefit cgm
pregnanc estim birth birth birth
intern mother gestat diabet assum approxim nine month
cgm usag patient gestat diabet estim total gestat diabet
market opportun grow
compound-annual-growth-rate intern estim total gestat diabet market
opportun grow compound-annual-growth-rate
hospit set estim hospit patient dysglycemia
 assum averag length stay day per patient estim total
cgm market opportun hospit set global
intern furthermor market research demonstr mm patient
admit hyperglycemia prior elect surgeri result delay increas length stay
hospit studi conduct hospit health network aac addit
suggest patient experi hyperglycemia patient experi
hypoglycemia admit hospit though condit prevent respect
cost health care expenditur incur peopl diabet higher rate
hospit admiss longer averag length stay per admiss make singl largest
contributor medic cost diabet approxim billion billion nation
expenditur hospit inpati care incur peopl diabet billion
directli attribut diabet popul combin signific cost incur
repres import unmet need provid opportun grow cgm market
mention work fda april temporarili allow use
hospit set suppli product key region affect recent data journal
diabet scienc technolog show peopl diabet hyperglycemia
hospit stay mortal rate greater four time patient without
diabet hyperglycemia addit patient develop hyperglycemia stay
evid diabet prior hospit die hospit accord wall street
journal hospit request devic plan produc sensor
hospit patient donat phone receiv hospit
non-insulin-intens type diabet estim approxim patient
 type diabet intens insulin estim approxim
patient basal insulin cgm immateri non-ii opportun current
estim believ cgm reach penetr time
program respons april announc new program provid
financi assist exist custom lost might lose insur coverag
suppli due plan launch program sever week may
potenti june part program compani plan provid elig custom two
suppli shipment cost custom includ one transmitt three box
three sensor provid expect impact headwind program busi
clariti unemploy rate patient base remain limit
order integr cgm product insulin deliveri system enter
partnership compani ypsome eli lilli novo nordisk tandem
diabet integr technolog partner insulin pump pen product offer
intend enabl partner insulin deliveri devic receiv display glucos read
technolog partner devic use glucos read semi-autom insulin deliveri
partnership posit benefit multipl commerci system next year
autom insulin deliveri smart pen
ypsome may ypsome announc partnership drive develop
hybrid close loop system initi cgm data sensor integr mylif
app yspome partnership mean cgm user user mylif ypsopump
insulin pump therapy-rel data mylif app smartphon
abl send data mylif app mylif cloud share caregiv
product integr avail europ late earli via free updat mylif
app without necess patient replac exist insulin pump
insulet corpor februari insulet corpor announc non-exclus
global commerci agreement combin current futur cgm system
tubeless insulin deliveri pod omnipod horizontm autom insulin deliveri
agreement omnipod horizon aid use sensor valu cgm
system predict glucos level automat adjust insulin dose help limit high low blood
glucos event horizon initi expect launch second half howev
paus horizon pivot studi correct softwar anomali modestli affect launch time
softwar updat success complet sent fda review
outbreak expect add month trial time line horizon expect
brought market first half
tandem diabet enter non-exclus develop agreement tandem
diabet inc juli integr futur gener tandem insulin pump
cgm system decemb fda approv slim insulin pump
control-iq technolog integr pump use cgm valu along
variabl predict glucos level minut ahead time adjust insulin deliveri accordingli
decemb sign commerci agreement smart pen offer
launch expect
companion medic june companion medic inc announc collabor
direct exchang cgm data insulin data inpentm compani softwar
applic inpen/clar report integr launch ada confer first
kind agreement pave way advanc diabet decis support import
tool insulin user requir input includ current glucos glucos trend carbohydr intak
accur insulin dose insulin-on-board collabor would allow compani offer
advanc featur algorithm improv in-the-mo decis peopl manag
diabet multipl daili inject
verili novemb enter amend restat collabor licens
agreement verili replac origin agreement verili august
elimin futur royalti oblig origin agreement agreement
verili continu jointli develop specif next-gener cgm product well one potenti
addit cgm product exclus commerci right also
exclus licens use verili intellectu properti result collabor well specif
verili patent develop manufactur commerci blood-bas interstiti
glucos monitor product gener also non-exclus licens right verili
intellectu properti right develop manufactur commerci type glucos
monitor product specif cgm-product companion softwar function up-front incent
payment made includ initi payment decemb share
common stock alloc verili onduo llc
complet develop oblig addit mileston payment may
made share common stock alloc verili onduo llc may becom due
payabl achiev futur product regulatori approv revenu mileston
beta bionic develop partner beta bionic develop ilet bionic
pancrea system insulin-onli configur expect launch bihormon
configur expect launch later
technolog collabor also enter sever partnership compani
unit health group livongo welldoc focus obtain patient data particularli patient
type diabet intens insulin therapi dxcm partnership unit health
group begun gener revenu though still insignificantli livongo approxim
peopl type diabet platform strong data yet gather due
unwilling mani patient conduct fingerstick elimin fingerstick gather data
cgm allow increas evid compani use futur potenti gain
broader commerci reimburs also on-going technolog collabor sever
januari center medicar medicaid servic establish classif
continu glucos monitor durabl medic equip dme medicar part
subject payment medicar specif coverag condit determin patient claim
claim basi local medicar administr contractor decis made possibl
fda approv non-adjunct indic mobil system medicar cover cgm
system dme benefit categori includ suppli necessari use devic
order cover benefit one compon cgm system must meet criteria
durabl medic devic receiv satisfi criteria
april announc pandem enforc clinic
indic therapeut coverag determin specif enforc
restrict type diabet beneficiari must requir demonstr need
frequent blood glucos test patient receiv therapeut cgm cover
medicar note decis intend allow patient monitor blood
glucos level given unpredict impact viru glucos level overal
health use could empow patient proactiv manag diabet prevent
necess diabet care hospit also note decis provid provid
abil allow diabet patient monitor glucos level adjust insulin dose
home note expans coverag intend valid
estim end dxcm averag medicar instal base patient
asp per patient per year januari becam
class ii icgm market cheapest cgm medicar channel could enabl
drive increas patient demand peopl type diabet type diabet intens insulin
addit roll walgreen medicar initi allow walgreen patient
abl pick sensor directli walgreen end transit
major medicar base expect eros medicar coverag
forthcom launch next gener system dxcm platinum system
classifi therapeut cgm remain inelig reimburs within medicare-
decemb coverag polici issu categori continu glucos
monitor devic seven largest privat third-parti payer number cover live
negoti contract rate seven payer platinum mobil system
mani polici restrict reimburs dme benefit requir patient compli
signific document requir demonstr medic necess howev
continu creat liber coverag polici payer includ gain reimburs
product pharmaci benefit
april unit healthcar began provid coverag peopl type diabet
intens insulin also note earn call anoth larg payer
expand type intens use polici though yet provid detail payer expect
coverag new payer take effect around middl coverag addit
medicar demonstr increas traction compani gain type intens insulin
market larg payer
intern nation payer germani g-ba began reimburs cgm peopl type
diabet type intens insulin provid access
cover live germani dxcm instal base germani grown ten time sinc
septemb germani feder joint committe made decis provid
reimburs cgm system condit believ meet japan
obtain approv februari compani refus reimburs fingerstick-level
devic favor gather necessari evid order establish new categori
reimburs real-tim cgm compani alreadi reimburs
shift pharmaci channel
intend shift commerci sale channel breakdown includ larger pharmaci portion
smaller dme portion long-term goal commerci base come
pharmaci channel end number dxcm pharmaci cover live higher
begin note earn call pharmaci continu
fastest grow channel compar medicar dme channel major new
patient addit come pharmaci channel quarter estim
end dxcm averag commerci instal base pharmaci
channel channel current remain minor portion commerci patient
pharmaci import channel effici expect reduc amount time
take patient get product week day reduc amount
paperwork involv get patient start devic expect shift pharmaci
channel help drive increas share among patient particularli type expect decreas
averag revenu per patient associ shift toward cheaper channel
pharmaci channel refer estim asp per patient per year dme channel
compar pharmaci channel compani expect
continu realiz reduct averag annual revenu per patient move pharmaci
channel dme channel compens via increas volum expect
price headwind shift medicar pharmaci manag note
came rang thu track toward target full year
sever clinic studi demonstr benefit cgm manag type insulin-
cgm associ improv less time hypoglycemia landmark studi conduct
juvenil diabet research foundat jdrf publish new england journal
medicin well extens phase studi publish diabet show
continu glucos monitor improv level reduc hypoglycemia incid patient
older patient age regularli use continu glucos monitor
multipl daili inject continu glucos monitor diabet diamond random
control trial first kind demonstr impact cgm
hypoglycemia particip multipl daili inject insulin regimen without insulin pump
therapeut intervent studi found user cgm system multipl daili inject
insulin therapi achiev averag reduct regular use week compar
baselin particip use cgm system also increas time spent target
rang spent less time hypoglycemia hyperglycemia particip use standard
blood glucos meter monitor glucos
subset diamond trial beck et al evalu cgm effect adult type
diabet use multipl daili inject insulin level cgm group
experienc decreas mean level compar group receiv
open-label crossov studi conduct et al evalu effect cgm
adult type diabet least multipl daili inject insulin studi
found use cgm associ lower patient popul compar
iqvia white paper describ potenti benefit cgm system suggest increas
time-in-rang industri standard type type insulin-us patient would result signific
cost save econom system well prevent major complic
standard medic diabet late ada recogn cgm use tool
diabet manag cite level evid type diabet level evid type
diabet pregnanc addit ada recommend continu access use close daili
possibl maxim benefit ada also recommend peopl type diabet test
blood glucos level three time per day significantli frequent test could
requir reach target safe without hypoglycemia
pilot studi irb type non-insulin-intens patient conduct intermountain
healthcar evalu whether six month cgm could improv patient outcom data show
improv glucos level fewer primari care specialti appoint emerg depart
encount lab order cumul bodi mass index improv improv
attribut subject util real-tim data
senior citizen subset diamond trial conduct ruedi et al found cgm use
associ improv reduc glycem variabl compar manag smbg
adult year older type type diabet
studi polonski et al show cgm user year age older
type type diabet report significantli fewer episod sever hypoglycemia significantli
greater well-b less hypoglycem fear less diabet distress non-cgm user
type non-intens insulin three studi current conduct patient type
diabet intens insulin one studi clinic trial identifi expect
complet may compar glycem quality-of-lif benefit diabet manag
use cgm self-monitor blood glucos patient type diabet use basal
insulin studi evalu patient type diabet oral medic regimen one
studi clinic trial identifi expect end decemb assess
patient abl make lifestyl chang result improv glycem control use
cgm versu self-monitor blood glucos test studi clinic trial identifi
expect complet august determin use cgm lifestyl modif
result better diabet control routin care
hospit set three studi current on-going evalu use cgm
patient hospit set two recent complet studi conduct
popul newest studi clinic trial identifi compar use
cgm sensor arteri glucos sampl analyz glucos meter adult patient intens
care unit studi expect complet june anoth studi clinic trial identifi
expect end decemb compar use cgm
point-of-car blood glucos meter diabet patient hospit hemodialysi
third studi clinic trial identifi also expect end decemb
evalu use cgm hospit patient type diabet
one studi complet octob clinic trial identifi evalu efficaci
continu glucos monitor use continu glucos monitor reduc hypoglycemia
improv safeti patient on-going post-gastr surgeri hypoglycemia anoth studi complet
decemb clinic trial identifi evalu feasibl use
elect gener surgeri patient diabet
pre-diabet pilot studi clinic trial identifi conduct use real-
time cgm educ tool patient prediabet diabet expect
complet june
pregnant women studi castorino et al publish april diabet technolog
found cgm accur safe pregnant women
random control conceptt trial conduct feig et al studi effect
cgm matern glucos control obstetr neonat health outcom women type
diabet group underw capillari glucos monitor cgm signific reduct
level week gestat compar group underw capillari glucos monitor
without cgm pregnant cgm user also spent time target glycem control rang less time
hyperglycem rang compar pregnant control group cgm group also experienc
shorter length stay hospit less neonat hypoglycemia reduc neonat intens care
admiss hour lower proport infant larg gestat age
anoth studi complet clinic trial identifi evalu role
cgm use either alon remot monitor capabl pregnant women type diabet
on-going trial earn call note time pivot trial would
delay minimum approxim six month due new trial clinic site paus
respons
on-going pilot studi approxim particip unit healthcar could help demonstr
valu cgm non-intens type market
on-going trial particip conduct intermountain healthcar clinic trial identifi
plan replic posit impact cgm observ previou intermountain
healthcar trial conduct shorter period time potenti optim patient outcom
afford intermountain intend build diabet program cgm base find
cgm market consist three major player
abt cgm offer includ freestyl libr flash glucos monitor system freestyl libr
launch europ approv fda juli next gener
freestyl libr system secur ce mark octob freestyl libr use
countri obtain partial full reimburs countri includ franc ireland japan
 canada libr roll ou fda review
freestyl libr cgm featur abbott freestyl libr system consist handheld reader
sensor worn back upper arm day unlik cgm system
includ transmitt handheld reader use scan sensor replac fingerstick
sensor display valu user respons scan system factori calibr user
calibr requir either manual data entri fingerstick data four real-world studi
present februari demonstr peopl use libr improv glucos control
increas time target glucos rang decreas time hyperglycemia hypoglycemia well
decreas averag glucos level three month note system passiv monitor
glucos level provid alarm alert without user-initi action scan view
detriment patient would alert experi glucos low high
forget scan sensor asleep
libr reimburs previous libr day approv fda septemb
replac bgm adult enabl patient make treatment decis base
inform provid devic enabl devic includ categori cgm
cover pave way medicar coverag obtain januari non-
medicar patient libr avail via prescript pharmaci durabl medic equip
supplier octob abbott omada health also announc partnership
integr libr omada digit care program mean omada would offer integr
solut employ health plan includ kaiser permanent cross shield
minnesota other elig patient type diabet would guid on-line physician
consult provid prescript libr receiv system via deliveri would
access omada data-pow human coach connect devic tailor curriculum
partnership thu expand libr access patient type diabet april
announc libr abl use hospit set
pandem accord fda
libr abt next gener devic abt next gener freestyl libr replac self-
monitor blood glucos without requir fingerstick offer option glucos alarm new
system offer customiz alarm glucos high low well technic featur notifi
user sensor commun reader patient scan sensor often
desir view glucos read similar origin freestyl libr price freestyl libr
system origin system similar also enter partnership
februari integr omnipod horizon autom insulin deliveri
abbott next gener freestyl libr sensor patient abl obtain suppli
conveni pay-as-you-go model podd abt abil sell pharmaci
support approv file libr icgm de novo process april
manag believ compani receiv fda approv libr well icgm design
note still work open item fda announc
recent commentari time note work finish item
regard open item fda earn call though specif updat time line
provid
remain commit expand larg cgm market opportun continu expand
manufactur capac regular cadenc given demand libr penetr
perspect abt recent public commentari frame cgm penetr
broader believ long runway year ahead multipl cgm
mdt cgm offer includ guardian connect cgm system approv fda march
becam avail mdt fiscal year may juli system receiv
ce mark juli launch outsid second quarter mdt fiscal year
begin countri europ asia pacif latin america
guardian connect cgm featur guardian connect cgm system smart hybrid closed-loop cgm
system intend alert patient diabet potenti blood glucos level high low
minut advanc system requir minimum two calibr fingerstick per day use
guardian sensor worn seven day discreet bluetooth transmitt send
glucos level read everi minut high glucos alert share via text messag
remot monitor via web-bas app allow other remain inform patient glucos level
peopl use guardian connect system also access sugar iq smart diabet assist
use technolog mdt strateg partner watson continu analyz glucos
level respons food intak insulin dose daili routin factor guardian connect
sugar iq app avail ios-bas mobil devic announc real world data
june collect peopl minimum five day
demonstr peopl use guardian connect system sugar iq app experienc
time rang use guardian connect alon
enter collabor payer manufactur enter
new value-bas agreement cross shield minnesota april agreement
provid member cross shield minnesota plan improv access
guardian connect system use time-in-rang achiev use system key metric
determin value-bas payment septemb also enter collabor
novo nordisk integr insulin dose data futur novo nordisk smart insulin pen cgm
devic guardian connect system novo nordisk novopen novopen
durabl smart insulin pen addit dispos pre-fil inject compat
android io devic expect launch start guardian connect system
updat integr data pen
continu wait non-adjunct label made pre-market approv pma submiss
fda juli request non-adjunct indic guardian conjunct
minim system approv non-adjunct indic would mean sensor accur
enough calcul insulin dose meal correct high glucos level approv would also
broaden patient access sinc medicar requir non-adjunct indic sensor reimburs
origin expect guardian cgm receiv non-adjunct claim end
push new time line given
futur devic includ synergi sensor beyond guardian cgm plan file
sensor may oct peg approv around
math note estim could affect approv time line
sensor reduc fingerstick still requir fingerstick calibr day
wear time announc june initi pivot trial next
gener guardian cgm sensor expect complet may evalu
particip type type diabet age seven day
beyond sensor plan file synergi sensor novemb april
peg approv around year-end adjust synergi
dispos sensor volum reduct still requir fingerstick calibr day would
requir over-tap would three-step insert process synergi sensor
step forward mdt cgm busi dont close gap complet
view earn call note compani make progress pivot trial
plan provid updat next earn call may
believ mdt diabet franchis continu disadvantag cgm
certain competit advantag mention mdt guardian cgm requir
two fingerstick per day wear time non-adjunct claim dxcm
abt libr requir fingerstick test calibr day wear time
non-adjunct claim allow medicar coverag origin expect guardian cgm
receiv non-adjunct claim end push new time line
given
accuraci perspect mean absolut rel differ mard commonli use measur
accuraci cgm system lower percentag indic greater accuraci guardian
connect system mard worn arm better score abt devic worn
arm score achiev sensor calibr twice per day sensor
achiev mard worn abdomen calibr twice per day
achiev better score worn abdomen calibr
term vs mard suggest better accuraci libr day
mard though ballpark also believ next gener
inher advantag real-tim compar libr next gener libr
flash glucos monitor system libr provid alarm alert without user-
initi scan libr option real-tim alarm still requir user-initi scan see
glucos read furthermor abil make diabet treatment decis take
maximum acetaminophen dose mg everi six hour could provid leg among
patient medic particularli diabet player look increas penetr hospit
set final success trial could neutral abt advantag sensor life inde
abl worn day intend
transmitt
receiv one
 sensor worn
back upper arm
urgent
io
sharabl
follow
frequenc
iphon later
android
later
data carelink
softwar
compani report websit clinic data secur llc
eversens cgm senseon hold inc medic technolog compani
focus develop long-term implant cgm system adult older diabet
compani fda-approv eversens cgm indic continu measur glucos level
day system consist fluorescence-bas sensor insert subcutan
upper arm health care provid brief in-offic procedur smart transmitt
worn sensor mobil app receiv data everi minut transmitt provid
vibratori alert high low glucos level remov recharg re-attach
skin without discard sensor
system receiv non-adjunct approv decemb allow patient dose insulin
base read system without confirmatori fingerstick howev even non-
adjunct label system still requir least two fingerstick per day calibr well
symptom match cgm inform patient take tetracyclin medic
system avail via prescript health care provid avail medicar
beneficiari design therapeut cgm reimburs
physician servic part medic servic benefit octob health servic
corpor hcsc cross shield began provid coverag eversens provid
access mm cover live across five state also began cover
insert procedur octob patient type type diabet
februari began cover provid access mm cover live patient
medicar advantag plan
promis clinic studi complet march evalu safeti efficaci
eversens system day particip diabet pre-market applic
submiss fda februari fda approv subgroup promis studi particip
continu studi day total feasibl data safeti accuraci
sensor could gather
kevin sayer execut chairman board director presid chief execut offic
join presid chief oper offic execut role mr sayer
respons research develop manufactur clinic regulatori financ sale
market function mr sayer instrument lead develop new technolog
tenur includ mobil cgm platinum
share well sever product launch europ
join mr sayer chief offic biosensor intern medic
technolog compani focus develop manufactur commerci medic
devic use intervent cardiolog critic care procedur mr sayer also serv chief
financi offic minim inc acquisit inc
mr sayer receiv master bachelor degre account inform system
quentin blackford execut vice presid chief offic chief oper offic
quentin blackford execut vice presid chief offic chief oper offic
mr blackford join chief offic commit increas
sharehold valu continu build upon credibl extern investor commun
manag overal financi strateg manag
prior mr blackford serv execut vice presid chief offic head
strategi corpor integr play key role navig compani
phase signific growth profit improv sinc mr blackford
instrument sever acquisit build upon portfolio product entri new
product segment geograph expans also work zimmer hold inc led
organ global financi plan analysi group addit serv director financ
control dental divis
mr blackford obtain certifi public account licens current inact receiv dual
bachelor scienc degre account busi administr grace colleg
steven pacelli execut vice presid strategi corpor develop mr pacelli
name evp strategi corpor develop tenur
serv role increas respons includ vice presid legal affair senior vice presid
corpor affair chief administr offic chief oper offic join mr
pacelli serv corpor attorney special financ merger acquisit gener
corpor matter also execut role gener counsel sever privat held compani
mr pacelli earn bachelor art univers california lo angel jd
univers virginia member state bar california
inc quarterli incom statement million except per share lnet gross total oper adj oper incom interest interest incom pre-tax incom incom adj net incom non-gaap share oper prior year result adjust includ non-cash interest expens conform new present compani report secur llc estim inc quarterli revenu build breakdowntot revenu chang chang chang chang total chang chang total breakdownsensor chang chang total chang chang qoq total chang chang qoq total chang chang total compani report secur llc estim medic technolog
markettot diabet patient chang type type insulin intens diabet patient total diabet intens intens insulin instal chang chang attrit instal chang instal chang per patient per chang type type ii revenu chang chang type revenu chang chang insulin intens ii type ii revenu chang chang non-ii type non-ii revenu mm chang y/i chang q/qseasonalityu commerci markettyp type revenu chang chang type ii revenu chang chang commerci type type iicommerci type type ii revenu chang chang medicar markettyp type revenu chang chang type ii revenu chang chang medicaremedicar revenu chang chang market intens insulin market type type revenu chang chang marketww revenu chang chang compani report secur llc estim inc
exhibit statement flow
inc balanc sheet fy end dec equival market receiv expens current cashnet properti plant leas right-of-us stockhold equityount payabl ru payrol relat leas liabil current current ltd revenu current debt leas liabil net current lt stock add earn deficit comp stockhold liabil stockhold compani report secur llc estim inc statement flows- fy end dec flow oper activ net oper asset expens leas right-of-us asset liabil payabl ru payrol relat revenu cash provid use oper flow invest activ purchas properti proce purchas available-for-sal market acquisitions/divestitures/oth equiti use invest flow financ activ net proce issuance/ purchas equiti proceeds/ payment provid financ exchang rate cash cash increas equival restrict begin equival restrict end compani report secur llc estim medic technolog
price target nc
price target assum revenu estim risk achiev price target
includ delay fda approv launch next gener devic slower-than-expect adopt
cgm competit
estim core continu glucos monitor cgm market one fastest
grow major med-tech market next five year see potenti upsid consensu sale
ep estim believ valuat reflect potenti sourc upsid
would prefer wait either better entri point greater visibl major new market
opportun type non-insulin intens recommend stock
inc medic devic compani focus continu glucos monitor cgm
devic diabet manag headquart san diego ca found
